ConductScience.org, home
A Study Evaluating the Efficacy and Safety of Guselkumab Administered Subcutaneously in Participants With Active Psoriatic Arthritis
API referenceFor AI assistants

Trial · NCT03158285

Participant flow33

How many started, completed or left each group, period by period.

1 to 20 of 33

Download this page as JSON
PeriodMilestoneGroupParticipantsUnits counted
Placebo-controlled Period: Week 0 - 24STARTEDPlacebo to Guselkumab 100 mg q4w246
Placebo-controlled Period: Week 0 - 24STARTEDGuselkumab 100 mg q8w248
Placebo-controlled Period: Week 0 - 24STARTEDGuselkumab 100 mg q4w245
Placebo-controlled Period: Week 0 - 24Pooled Population: Enthesitis AssessmentPlacebo to Guselkumab 100 mg q4w255
Placebo-controlled Period: Week 0 - 24Pooled Population: Enthesitis AssessmentGuselkumab 100 mg q8w230
Placebo-controlled Period: Week 0 - 24Pooled Population: Enthesitis AssessmentGuselkumab 100 mg q4w243
Placebo-controlled Period: Week 0 - 24Pooled Population: Dactylitis AssessmentPlacebo to Guselkumab 100 mg q4w154
Placebo-controlled Period: Week 0 - 24Pooled Population: Dactylitis AssessmentGuselkumab 100 mg q8w160
Placebo-controlled Period: Week 0 - 24Pooled Population: Dactylitis AssessmentGuselkumab 100 mg q4w159
Placebo-controlled Period: Week 0 - 24COMPLETEDPlacebo to Guselkumab 100 mg q4w240
Placebo-controlled Period: Week 0 - 24COMPLETEDGuselkumab 100 mg q8w240
Placebo-controlled Period: Week 0 - 24COMPLETEDGuselkumab 100 mg q4w236
Placebo-controlled Period: Week 0 - 24NOT COMPLETEDPlacebo to Guselkumab 100 mg q4w6
Placebo-controlled Period: Week 0 - 24NOT COMPLETEDGuselkumab 100 mg q8w8
Placebo-controlled Period: Week 0 - 24NOT COMPLETEDGuselkumab 100 mg q4w9
Active Treatment Period: Week 24 - 52STARTEDPlacebo to Guselkumab 100 mg q4w238
Active Treatment Period: Week 24 - 52STARTEDGuselkumab 100 mg q8w240
Active Treatment Period: Week 24 - 52STARTEDGuselkumab 100 mg q4w234
Active Treatment Period: Week 24 - 52COMPLETEDPlacebo to Guselkumab 100 mg q4w228
Active Treatment Period: Week 24 - 52COMPLETEDGuselkumab 100 mg q8w234

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT03158285/flow

API referenceFor AI assistants